GLP Watchdog

Hers vs MEDVi

Hers has an open FDA warning letter dated September 9, 2025. MEDVi has an open FDA warning letter dated February 20, 2026. On compounded semaglutide injection, the standing prices are within $1 a month of each other: $199 at Hers and $199 at MEDVi.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / MEDVi

Hers logo

Hers

6.8/10

MEDVi logo

MEDVi

7.7/10

FDA warning letters
Pharmacy
Lowest standing price
$199/moCompounded semaglutide injection
$199/moCompounded semaglutide injection
States
All 50 states
All 50 states
Checked
Prices captured Record checked September 2026
Prices captured Record checked October 2026
Visit Hers
Visit MEDVi

Neither Hers nor MEDVi pays us. Links to them earn nothing. Scores: Hers 6.8, MEDVi 7.7. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. MEDVi has an open FDA warning letter dated February 20, 2026.

  2. 02

    Hers names three pharmacies. MEDVi names three pharmacies, all 503A.

  3. 03

    On compounded semaglutide injection, the standing prices are within $1 a month of each other: $199 at Hers and $199 at MEDVi.

  4. 04

    Only Hers lists a price for brand-name tirzepatide pen.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

MEDVi

Compounded semaglutide injection

$199/mo

$2,388 a year

$199/mo

$2,388 a year

Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Medication, clinician visits, shipping, coaching
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None; billed monthly
Refunds
No refund guaranteed once the pharmacy has processed an order
Full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed
Early-exit fee
Not stated
None stated

Read off each seller’s own pages. Hers: September 28, 2026. MEDVi: October 25, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • Sells brand-name tirzepatide pen, which MEDVi does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

The case for MEDVi

7.7/10
  • Price includes clinician visits and coaching
  • Open FDA warning letter, February 20, 2026
Visit MEDVi

Scores

Hers 6.8 · MEDVi 7.7 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
5.0

Effectiveness25%

10.0A
vs
B
10.0

User Experience15%

8.0A
vs
B
8.0

Trust & Safety15%

7.0A
vs
B
6.0

Accessibility10%

10.0A
vs
B
10.0

Support10%

3.0A
vs
B
8.5

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs MEDVi: questions

Hers has an open FDA warning letter dated September 9, 2025. MEDVi has an open FDA warning letter dated February 20, 2026. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. MEDVi names three pharmacies, all 503A. A 503A pharmacy compounds for named patients on a prescription; a 503B outsourcing facility is registered with FDA and inspected under federal manufacturing rules.
Neither, by more than $1 a month. Hers charges $199 a month and MEDVi $199 a month.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. MEDVi states you can cancel at any time; refunds: full refund if medically disqualified, or if canceled within 72 hours before any service; none for months already billed.
Neither Hers nor MEDVi pays us. Links to them earn nothing. Scores: Hers 6.8, MEDVi 7.7.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks